GPT Healthcare Ltd

GPT Healthcare Ltd has launched its Second 100 Days Campaign, "Saksham Niveshak," in line with the IEPFA's directive. This initiative aims to help shareholders claim unpaid/unclaimed dividends and complete KYC formalities to prevent their transfer to the IEPF. The company has dispatched letters to affected shareholders and provided details on its website. Shareholders are urged to update KYC, claim dividends, and submit necessary forms (ISR-1, ISR-2, ISR-3, SH-13, SH-14) to the Registrar and Transfer Agent, MUFG Intime India Private Limited, or their respective depositories to ensure timely credit of dividends and avoid transfer of shares and dividends to the IEPF.

GPT Healthcare Limited reported its financial results for Q4 and the full financial year ended March 31, 2026. For Q4FY26, total revenue increased by 24.30% year-on-year to ₹128.0 crore, with Profit After Tax (PAT) growing 13.00% to ₹14.7 crore. EBITDA for the quarter rose 12.27% to ₹25.0 crore. For the full FY26, revenue stood at ₹478.5 crore, a 15.14% increase from FY25, while PAT declined 15.43% to ₹42.2 crore. Operational highlights include an ARPOB of ₹39,243 and an improved occupancy rate of 55.90% (excluding the newly commenced Raipur facility). The Raipur Hospital successfully began operations, and an MoU was signed for a 150-bed facility in Jamshedpur.

GPT Healthcare Ltd's Board of Directors has recommended a final dividend of 15%, which is ₹1.50 per equity share (face value of ₹10 each) for the financial year ended March 31, 2026. This recommendation is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 6, 2026, which will be held via video conferencing. The record date for determining dividend entitlement is July 30, 2026, and the book closure will be from July 31, 2026, to August 6, 2026. If approved, the dividend will be paid within 30 days of declaration at the AGM.

GPT Healthcare Ltd. will hold its 37th Annual General Meeting on August 6, 2026, via video conferencing. The board has recommended a final dividend of 15% (₹1.50 per share) for FY26, subject to shareholder approval. The record date for dividend entitlement is July 30, 2026. The book closure will be from July 31, 2026, to August 6, 2026.

GPT Healthcare Ltd has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The results, approved by the Board of Directors on May 18, 2026, have been audited by S R Batliboi & Co LLP, who issued an unmodified opinion. The company does not have any subsidiaries or associates, so consolidated financial results were not required.

GPT Healthcare Ltd's Board of Directors met on May 18, 2026, approving the Audited Financial Results for the fourth quarter and full financial year ended March 31, 2026, with an un-modified audit opinion. The Board recommended a final dividend of ₹1.50 per equity share (15%) for FY26, pending shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 6, 2026. The record date for dividend entitlement is set for July 30, 2026. Additionally, the Board approved the reappointment of statutory, cost, and internal auditors for FY26-27, re-appointed two independent directors, and approved the continuation of another independent director past 75 years of age. Increases in remuneration for two relatives of directors and consultancy fees for a non-executive director were also approved.

GPT Healthcare Ltd has scheduled a Board of Directors meeting on May 18, 2026, to consider and approve the audited financial results for the fourth quarter and financial year ended March 31, 2026. The board will also consider recommending a final dividend for FY 2025-26. The trading window remains closed until May 20, 2026, following the meeting.

GPT Healthcare Ltd has informed about the resignation of Mr. Debashis Dhar, Senior Vice President and Chief Business Development Officer, and one of the Statutory Auditors (SMP) of the company. Mr. Dhar has resigned due to personal reasons, effective from the close of business hours on April 2, 2026. He was appointed as Senior Vice President and Chief Business Development Officer and joined the company's leadership, contributing to its growth and evolution. The company and Mr. Dhar have had a successful professional relationship, with Mr. Dhar expressing gratitude for the trust, encouragement, and guidance received during his tenure.

GPT Healthcare Ltd has announced the closure of the trading window for dealing in the securities of the company by the designated persons and their immediate relatives. The closure will be in effect from Wednesday, April 01, 2026 till 48 hours after the declaration of the Audited Financial Results for the 4th quarter and financial year ending on March 31, 2026. The date of the Board meeting for consideration and approval of the Audited Financial Results will be intimated in due course. The decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company’s Code of Conduct. All the Designated Persons of the Company and their immediate relatives are advised not to trade in the securities of the Company during the aforesaid trading window closure period.

GPT Healthcare Limited reported its financial results for the 9-month period ended December 31, 2025 (9MFY26). The company's revenue stood at Rs 351 crore, representing a 12% year-over-year growth. The company maintained an affordable ARPOB at INR 38,797 and recorded steady improvement in occupancy rates at 55%, driven by higher patient volumes and efficient capacity utilization. The Raipur facility is scaling efficiently and the project work at the upcoming Jamshedpur facility is progressing as planned.